EFFECTIVENESS OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST LIRAGLUTIDE IN THE TREATMENT OF OBESITY (literature review)
DOI:
https://doi.org/10.21856/j-PEP.2023.1.08Keywords:
obesity, overweight, glucagon-like peptide-1 receptor agonist, liraglutide, type 2 diabetes mellitus, arterial hypertensionAbstract
Obesity is an extremely common chronic disease. The main directions in the treatment of obesity are: lifestyle modification and pharmacotherapy. Among the existing pharmacological drugs that are used to treat obesity, glucagon-like peptide-1 receptor agonists, primarily liraglutide, are of particular interest.
This review presents the results of a number of studies that are devoted to the study of the efficacy and safety of liraglutide in the treatment of overweight and obesity, including patients with type 2 diabetes mellitus. Literature data indicate that the use of liraglutide causes a persistent decrease in body weight in most patients with overweight and obesity, leads to a significant improvement in carbohydrate and lipid metabolism, as well as to a decrease in the severity of obesity-associated arterial hypertension.
An important indication for the use of liraglutide is not only obesity, but also type 2 diabetes mellitus, which occurs against the background of overweight. The result of treatment with liraglutide in obese patients without type 2 diabetes mellitus is a reduction the risk of developing the latter, and, in obese patients, regardless of the presence or absence of diabetes, inhibition of the progression of atherosclerosis, hypertension and a decrease in cardiovascular risk. In addition, the use of liraglutide is a promising treatment for obesity-associated diseases such as obstructive sleep apnea syndrome, polycystic ovary syndrome in women, and male infertility.
Liraglutide shows comparable effectiveness in the ability to reduce body weight in obese patients compared to other drugs of a similar nature, but, at the same time, leads to the most pronounced decrease in cardio-metabolic disorders in this category of patients.
References
World Health Organization. Obesity: preventing and managing the global epidemic, Geneva,1997.
Koval SM, Reznik LA, Miloslavsky DK, et al. Probl Endocrine Pathol 2020;74(4): 66-70. https://doi.org/10.21856/j-PEP.2020.4.08
Koval SM, Reznik LA, Starchenko TG, et al. Probl Endocrine Pathol 2021;77(3): 47-51. https://doi.org/10.21856/j-PEP.2021.3.06
Koval SM, Mysnichenko OV, Penkova MY. Probl Endocrine Pathol 2020;74(4): 60-65. https://doi.org/10.21856/j-PEP.2020.4.07
Fadjejenko GD, Nikiforova JaV. Ukr Terapevt Zhurn 2019;(1): 7-13. https://doi.org/10.30978/UTJ2019-1-7
Garvey WT, Mechanick JI, Brett EM, et al. Endocr Pract 2016;22(3): 1-203. https://doi.org/10.4158/EP161365.GL
Biddle S, García Bengoechea E, Pedisic Z, et al. Curr Obes Rep 2017;6(2): 134-147. https://doi.org/10.1007/s13679-017-0256-9
Wharton S, Lau DCW, Vallis M, et al. CMAJ 2020;192(31): E875-E891. https://doi.org/10.1503/cmaj.191707
Mechanick JI, Hurley DL, Garvey WT. Endocr Pract 2017;23(3): 372-378. https://doi.org/10.4158/EP161688.PS
Heymsfield SB, Wadden TA. N Engl J Med 2017;376(3): 254-266. https://doi.org/10.1056/NEJMra1514009
Fruhbeck G, Busetto L, Dicker D, et al. Obes Facts 2019;12(2): 131-136. https://doi.org/10.1159/000497124
Singh AK, Singh R. Expert Rev Clin Pharmacol 2020;13: 53-64. https://doi.org/10.1080/17512433.2020.1698291
Fitch A, Ingersoll AB. Postgrad Med 2021;133(3): 310-319. https://doi.org/10.1080/00325481.2020.1845534
Alruwaili H, Dehestani B, le Roux CW. Clin Pharmacol 2021;13: 53-60. https://doi.org/10.2147/CPAA.S276085
Shah M, Vella A. Rev Endocr Metab Disord 2014;15(3): 181-187. https://doi.org/10.1007/s11154-014-9289-5
van Bloemendaal L, Ten Kulve JS, la Fleur SE, et al. J Endocrinol 2014;221(1): T1-16. https://doi.org/10.1530/JOE-13-0414
Mehta A, Marso SP, Neeland IJ. Obes Sci Pract 2017;3(1): 3-14. https://doi.org/10.1002/osp4.84
Astrup A, Rossner S, Van Gaal L, et al. Lancet 2009;374: 1606-1616. https://doi.org/10.1016/S0140-6736(09)61375-1
Astrup A, Carraro R, Finer N, et al. Int J Obes (Lond) 2012;36(6): 843-854. https://doi.org/10.1038/ijo.2011.158
Pi-Sunyer X, Astrup A, Fujioka K, et al. N Engl J Med 2015;373(1): 11-22. https://doi.org/10.1056/NEJMoa1411892
le Roux CW, Astrup A, Fujioka K, et al. Lancet 2017;389(10077): 1399-1409. https://doi.org/10.1016/S0140-6736(17)30069-7
Davies MJ, Bergenstal R, Bode B, et al. JAMA 2015;314(7): 687-699. https://doi.org/10.1001/jama.2015.9676
Wadden TA, Hollander P, Klein S, et al. Int J Obes (Lond) 2013;37(11): 1443-1451. https://doi.org/10.1038/ijo.2013.120
Lundgren JR, Janus C, Jensen SBK, et al. N Engl J Med 2021;384(18): 1719-1730. https://doi.org/10.1056/NEJMoa2028198
Blackman A, Foster GD, Zammit G, et al. Int J Obes (Lond) 2016;40(8): 1310-1319. https://doi.org/10.1038/ijo.2016.52
Goncharova OA, Arkhypkina TL, Liubymova LP. Probl Endocrine Pathol 2022;79(2): 105-111. https://doi.org/10.21856/j-PEP.2022.2.15
Andersen E, Juhl CR, Kjøller ET, et al. Hum Reprod 2022;37(7): 1414-1422. https://doi.org/10.1093/humrep/deac096
ISSN 
ISSN 
